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Aldosterone
and corticosterone bind to mineralocorticoid (MR) and glucocorticoid
receptors (GR), which, upon ligand binding, are thought to translocate
to the cell nucleus to act as transcription factors. Mineralocorticoid
selectivity is achieved by the 11-hydroxysteroid dehydrogenase type
2 (11-HSD2) that inactivates 11-hydroxy glucocorticoids. High
expression levels of 11-HSD2 characterize the aldosterone-sensitive
distal nephron (ASDN), which comprises the segment-speciﬁc cells of
late distal convoluted tubule (DCT2), connecting tubule (CNT), and
collecting duct (CD). We used MR- and GR-speciﬁc antibodies to
study localization and regulation of MR and GR in kidneys of rats
with altered plasma aldosterone and corticosterone levels. In control
rats, MR and GR were found in cell nuclei of thick ascending limb
(TAL), DCT, CNT, CD cells, and intercalated cells (IC). GR was also
abundant in cell nuclei and the subapical compartment of proximal
tubule (PT) cells. Dietary NaCl loading, which lowers plasma aldo-
sterone, caused a selective removal of GR from cell nuclei of 11-
HSD2-positive ASDN. The nuclear localization of MR was unaf-
fected. Adrenalectomy (ADX) resulted in removal of MR and GR
from the cell nuclei of all epithelial cells. Aldosterone replacement
rapidly relocated the receptors in the cell nuclei. In ASDN cells,
low-dose corticosterone replacement caused nuclear localization of
MR, but not of GR. The GR was redistributed to the nucleus only in
PT, TAL, early DCT, and IC that express no or very little 11-HSD2.
In ASDN cells, nuclear GR localization was only achieved when
corticosterone was replaced at high doses. Thus ligand-induced nu-
clear translocation of MR and GR are part of MR and GR regulation
in the kidney and show remarkable segment- and cell type-speciﬁc
characteristics. Differential regulation of MR and GR may alter the
level of heterodimerization of the receptors and hence may contribute
to the complexity of corticosteroid effects on ASDN function.
aldosterone; corticosterone; 11-hydroxysteroid dehydrogenase type 2
THE MINERALOCORTICOID RECEPTOR (MR) and the glucocorticoid
receptor (GR) mediate the effects of corticosteroids in virtually
all organs, including the brain, heart, lung, and kidney. Renal
MR- and GR-dependent signaling is involved in the control of
electrolyte transport (56) and regulation of cell metabolism
including gluconeogenesis and ammoniagenesis (30). Studies
on gene-modiﬁed mice conﬁrmed the pivotal physiological
relevance of both receptors. MR- and GR-deﬁcient mice die
shortly after birth due to severe salt wasting or impaired lung
maturation, respectively (3, 6).
The MR and the GR are ligand-dependent transcription
factors, that share high homologies in the DNA- and ligand-
binding domains, and which have distinct afﬁnities for corti-
costeroid hormones (57). While the afﬁnity of the MR for
aldosterone and physiological glucocorticoids (i.e., corticoste-
rone in rodent and cortisol in human) is high (Kd in the range
from 0.5 to 3 nM), the GR has 10 times lower afﬁnity for
these steroids (Kd in the range from 20 to 65 nM) (1).
Ligand-binding induces a dimerization of the receptors, which
is thought to be followed by the translocation of the receptor-
ligand complex to the cell nucleus where it then binds to
speciﬁc MR- and GR-dependent response elements in the
promoter regions of target genes (56). MR and GR may not
only form homodimers (MR-MR or GR-GR) but also het-
erodimers (MR-GR), which may differentially activate or
repress gene networks and hence may contribute to the
signiﬁcant complexity of MR- and GR-dependent signal-
ing (14).
Because physiological glucocorticoids circulate in the blood
plasma at 100–1,000 times higher concentrations than aldoste-
rone, mammalian species had to develop mechanisms to pro-
vide mineralocorticoid speciﬁcity to target cells (14). One
major mechanism that evolved and protects the MR and GR
from glucocorticoid access is mediated by the enzyme 11-
hydroxysteroid dehydrogenase type 2 (11-HSD2), which rap-
idly metabolizes physiological glucocorticoids into metabolites
that have weak or no afﬁnity for the receptors. Accordingly,
tissues with high aldosterone responsiveness are characterized
by high expression levels of 11-HSD2 (4, 14, 56). Within the
rodent kidney, 11-HSD2 is highly abundant in the late distal
convoluted tubule (DCT2), the connecting tubule (CNT), and
the collecting duct (CD) (4), which hence form the so-called
aldosterone-sensitive distal nephron (ASDN) (36). Along the
ASDN, aldosterone stimulates sodium reabsorption via activa-
tion of the epithelial sodium channel (ENaC) and the Na-K-
ATPase that are expressed in the apical and basolateral plasma
membrane of the ASDN cells, respectively (56).
Although the function of mineralo- and glucocorticoids as
well as their receptors appears to be well established and
several studies addressed the localization of MR and GR along
the mammalian nephron, the precise cellular and subcellular
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localization of MR and GR in speciﬁc nephron portions and
cell types under normal and steroid-stimulated conditions are
still unclear. Immunohistochemical, hormone binding, and RT-
PCR studies revealed the MR unambiguously along the ASDN
(4, 7, 10, 13, 32, 37, 45, 53), but MR localization in upstream
nephron portions such as the thick ascending limb (TAL) is
less clear. Similarly, a convincing demonstration of MR ex-
pression in intercalated cells in the kidney in vivo is lacking.
So far, only some expression data on immunoisolated cells
from rabbit CD suggested the expression of the MR in princi-
pal cells and at least some subtypes of intercalated cells (40).
However, immunohistochemical studies failed to detect MR in
intercalated cells in the collecting system of rat kidneys (4, 13).
In addition to the ambiguities regarding the cellular distribution
of MR and GR, little is known about the corticosteroid-
dependent regulation of MR and GR in the kidney in vivo.
Nuclear translocation of the MR upon ligand binding has been
well documented in in vitro systems (16), but an in vivo
demonstration of this effect in the kidney is lacking. In fact,
previous studies did not detect any substantial effect of corti-
costeroid dosing on the subcellular localization of MR and GR
in renal epithelial cells in vivo (13, 32, 37).
Therefore, the aim of the present study was to reinvestigate
the cellular localization of MR and GR along the rat nephron
and to study the regulation of the subcellular localization of
MR and GR in response to altered corticosteroid hormone
levels by using a set of highly speciﬁc antibodies against MR
and GR.
MATERIALS AND METHODS
Animal experiments. Animal studies were conducted in accor-
dance with Swiss animal welfare regulations and after written
consent of the veterinarian ofﬁce of the Canton of Fribourg,
Switzerland. Kidneys were harvested from 1) 6- to 8-wk-old male
transgenic MRAQP2cre mice with targeted deletion of the MR in the
segment-speciﬁc cells of the CD and late CNT (46), 2) from male
newborn GR-deﬁcient mice with targeted deletion of GR in all cell
types (6), and 3) from male 6- to 8-wk-old Wistar rats (Charles
River Laboratories, Elevage Janvier, France). Mice and rats had
free access to tap water and were fed with a standard laboratory
chow containing 0.3% sodium.
Three different types of experiments were performed: experiment
1, where rats received either a standard diet (Control, 0.3% Na) or a
high-sodium (5% Na) diet for 5 days (High Na); experiment 2,
where rats were adrenalectomized and received either only an intra-
venous infusion of vehicle (ADX) or of a physiologically relevant
concentration of aldosterone (1 g·kg body wt1·h1; ADXAldo),
and the vehicle and aldosterone were infused with a perfusor for 4 h
starting 2 days after adrenalectomy; and experiment 3, where rats were
adrenalectomized and received either a subcutaneous infusion of
vehicle (ADX), low-dose corticosterone (1 g·kg body wt1·h1;
ADXLow Cortico), or high-dose corticosterone (100 g·kg body
wt1·h1; ADXHigh Cortico). Vehicle and corticosterone were
infused via osmotic minipumps for two days starting immediately
after ADX. At least ﬁve rats per group were studied.
For ADX, animals were anesthetized with a mixture (450 l/kg
body wt ip) containing Dormitor (1 mg/ml, Pﬁzer, Karlsruhe, Ger-
many), Climasol (10 mg/ml, Gräub, Bern, Switzerland), and Fentanyl
(0.5 mg/ml, Janssen Cilag, Baar, Switzerland). Bilateral ADX was
performed. After surgery, rats were awakened with a mixture (680
l/g body wt sc) containing Antisedan (1 mg/ml, Pﬁzer), Sarmasol (1
mg/ml, Gräub), and Narcan (0.4 mg/ml, Opopharma, Zurich, Swit-
zerland). All animals received a nonsteroidal pain killer subcutane-
ously intraoperatively.
For intravenous aldosterone application, the rats were anesthetized
with the same mixture as for ADX. Surgical preparation included
cannulation of the jugular vein and suprapubic cannulation of the
urinary bladder for urine collection. Urine was collected for the last 15
min of every full hour. After cannulation of the jugular vein, an
intravenous infusion with 0.9% NaCl was started at the rate of 0.72
ml·kg1·min1 for 30 min and then maintained at the rate of 0.36
ml·kg1·min1 for the rest of the experiment. For the aldosterone-
treated rats, 45 min after the infusion was started urine was collected
for 15 min (end of the control period). One hour after the start of the
infusion, aldosterone (Sigma-Aldrich, Epalinges, Switzerland) was
added to the solution at a concentration of 129 nmol/l (46 g/l),
resulting in a constant delivery of 1 g·kg body wt1·h1. Animals
were killed 3 h after starting the aldosterone treatment. Control
animals were treated for 4 h with 0.9% NaCl only.
Animals of the corticosterone-treated groups received an osmotic
minipump (Alzet, Charles River) during the adrenalectomy that de-
livered a constant rate of corticosterone (Sigma-Aldrich) solved in
0.9% NaCl for the following days. Control animals received the
vehicle only. The physiological effects of corticosterone were studied
in a different series of animals that were prepared according to the
same protocol and administered the same amounts of corticosterone or
carrier solution. Animals were kept in individual metabolic cages for
24 h before adrenalectomy and death, respectively. Urinary sodium
and potassium concentrations in the collected samples were measured
using an ion-selective electrode provided by Roche Diagnostics. We
did not take any blood samples from the rats as previous experiments
showed that this compromises tissue perfusion ﬁxation likely due to
hypovolemic vasoconstriction.
RT-PCR on mouse microdissected tubules. Isolated tubules were
obtained by microdissection. After anesthesia (thiopental, 5 mg/100 g
body wt), the left kidney was perfused with liberase blendzyme II (40
g/ml, Roche, Basel, Switzerland) dissolved in DMEM-F12 (GIBCO,
Basel, Switzerland). Thin pyramids cut along the corticomedullary
axis were incubated for 30 min at 37°C and 5% CO2 in the DMEM-
F12 containing 40 g/ml liberase. The pyramids were then rinsed in
the microdissection solution and kept on ice. The segments were
microdissected at 4°C under stereomicroscopic observation in the
same medium (DMEM-F12). Glomeruli, PCT, and proximal straight
tubules, outer medullary and cortical TAL, DCT, CNT, and the
different parts of the CD were isolated. Total RNA were extracted
from 25 isolated glomeruli and 20 mm of each nephron segment.
Isolation of tubule RNA was performed according to the standard
TRIzol method protocol (Invitrogen). RT was performed using Su-
perscript II (Invitrogen) with 4 l of 5 RT buffer, 1 l of 50 M
random hexamers (Applied Biosystems, Foster City, CA), 1 l 20
mM dNTP (Promega, Wallisellen, Switzerland), and 4 l of tubule
RNA diluted in H2O (up to 20 l). For analysis of MR expression
along the nephron, standard PCR was carried out on 25% of the total
amount of RT product from 20 mm of each isolated nephron segment.
MR and -actin primers were used as previously described (3, 8). For
GR, the following primers were applied: 5=-GAAAGCATTG-
CAAACCTCAA-3= and 5=-TCTGTTTTCACTGGGGCA-3=. The fol-
lowing conditions for the PCR were used: annealing temperature
60°C; annealing time 1 min; elongation temperature 72°C; elongation
time 45 s; 35 cycles. Total volume of PCR was loaded on a 1%
agarose gel; electrophoresis was done for 30 min (constant 80 V).
Western blot analysis. mCCD cells were grown on collagen-treated
semipermeable support (Transwell, Corning Costar, Cambridge, MA)
(19). For GR detection, cells were lysed in 100 l lysis buffer [150
mM NaCl, 50 mM Tris·HCl (pH 8), 1% Triton X-100, 0.5 mM
2-aminoethylbenzenesulfonyl ﬂuoride (Pefabloc; Roche)]. Fifty mi-
crograms of total protein was separated by SDS-PAGE and blotted
on a nitrocellulose membrane. For MR detection, cells were lysed in
buffer containing 0.12 M molybdate. Homogenized cells were then
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centrifuged for 20 min at 20,000 g to accumulate cytosolic proteins in
the supernatant. Fifty micrograms of the cytosolic protein fraction was
further separated by SDS-PAGE and blotted on a nitrocellulose
membrane.
After transfer, membranes were incubated for 1 h in blocking
solution (5% low-fat milk in TBS-0.04% Tween) to block unspeciﬁc
binding sites. The primary antibodies were applied for 16 h at 4°C.
Subsequently, the membranes were incubated for 2 h at room tem-
perature with the secondary horseradish peroxidase-labeled anti-rabbit
and anti-mouse antibodies, respectively. Chemiluminescence detec-
tion (enhanced ECL detection kit, Amersham) was used to visualize
antibody-binding on X-ray ﬁlm. All antibodies were diluted in block-
ing solution [MR: rMR1–18 (24) 1:500; GR: M-20 (sc-1004, 1:2,000,
Santa Cruz Biotechnology, Heidelberg, Germany); horseradish per-
oxidase-labeled goat-anti-rabbit IgG and goat-anti mouse IgG (1:
2,000, Jackson ImmunoResearch Laboratories, West Grove, PA)].
Immunohistochemistry. The kidneys of anesthetized adult rats and
mice were ﬁxed by vascular perfusion with 3% paraformaldehyde and
processed for immunohistochemistry as previously described (34).
The kidneys of newborn GR/ and GR/ mice were ﬁxed by
immersion in 4% paraformaldehyde for 48 h at 4°C and embedded in
parafﬁn according to routine procedures. Serial cryosections or par-
afﬁn sections (4 m thick each) were incubated with one of the
following primary antibodies: [monoclonal mouse anti-rat-MR
(rMR1–18) (24), polyclonal rabbit anti-mouse-GR (M-20, sc-1004
Santa Cruz Biotechnology), polyclonal rabbit anti-human-GR (PA1–
511A; Afﬁnity Bioreagents-Thermoscientiﬁc, Rockford, IL), poly-
clonal rabbit anti-rat Na-K-2Cl cotransporter (NKCC2) antibody (58),
polyclonal rabbit anti-rat Na-Cl cotransporter (NCC) antibody (35),
polyclonal rabbit anti-rat -ENaC antibody (58), polyclonal sheep
anti-rat 11-HSD2 antibody (Chemicon Millipore, Hofheim, Ger-
many), and polyclonal rabbit anti-rat calbindin D28K (Swant, Bell-
inzona, Switzerland)]. The binding sites of the primary antibodies
were revealed by Cy3-conjugated goat anti-rabbit IgG (Jackson Im-
munoResearch Laboratories) and FITC-conjugated goat anti-mouse
IgG (Jackson ImmunoResearch Laboratories), respectively. All anti-
bodies dilutions were in PBS-1% BSA.
Evaluation of immunoﬂuorescence. The sections were studied with
a Zeiss ﬂuorescence microscope by three investigators (D. Acker-
mann, M. Carrel, and J. Lofﬁng), who were blinded to the treatment
of the animals. Tubular segments were identiﬁed according to stan-
dard morphological criteria. TAL, DCT, CNT, and CD were distin-
guished on the basis of their localization in the cortical labyrinth and
in the medullary rays, respectively. Qualitative judgments regarding
immunostainings were similar for all investigators.
Statistics. Results are expressed as means  SE. The data followed
a normal distribution, and the groups were compared using a two-
sided unpaired t-test.
RESULTS
Localization of MR and GR mRNA along the mouse
nephron. We used RT-PCR to detect MR and GR transcripts in
microdissected nephron portions from normal mice (Fig. 1).
Fig. 1. Distribution of mRNA encoding for mineralocorticoid (MR) and
glucocorticoid receptors (GR) along the mouse nephron. RT-PCR was per-
formed on microdissected nephron portions. Glomeruli, proximal convoluted
and straight tubules (PCT, and PST, respectively), outer medullary and cortical
thick ascending limbs (OMTAL and CTAL, respectively), distal convoluted
tubules (DCT), connecting tubules (CN), and cortical, outer medullary, and
inner medullary collecting ducts (CCD, OMCD, and IMCD, respectively) were
microdissected from murine kidney; mRNA was isolated from 25 glomeruli
and 20 mm of nephron segment each. RT-PCR was performed using primers
speciﬁc for MR, GR and actin as described in MATERIALS AND METHODS. The
ampliﬁed fragments were veriﬁed by sequencing. Detection of actin mRNA
was used as a control.
Fig. 2. A: detection of MR and GR in the mouse collecting duct cell line
mCCDcl1. The mCCD cells were grown on permeable supports and then
processed for either immunoblotting (left) or immunocytochemistry (right) as
described in MATERIALS AND METHODS. In immunoblots, MR and GR
antibodies (rMR1–18 and M-20, respectively) detect bands of the expected
sizes for MR (107 kDa) and GR (94 kDa), respectively. In immunocyto-
chemistry the MR and GR antibodies (rMR1–18 and M-20, respectively)
show the expected staining of cell nuclei that were counterstained with the
DNA dye 4,6-diamidino-2-phenylindole (DAPI). Scale bar 	 
5 m.
B: detection of MR and GR in kidneys of control mice (MR/ and
GR/) and mice with either a collecting system-speciﬁc deletion of the
MR (MRAQPcre) or constitutive deletion of the GR in all organs. While MR
and GR are readily detectable in control mice, MR and GR staining are
absent in cells with targeted deletion of MR and GR. Asterisks indicate
medullary collecting ducts in MR / and MR/ mice. The used
antibodies are indicated in brackets. Scale bar 	 
20 m.
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Messenger RNA for MR was present in all distal tubules,
including medullary and cortical TAL, DCT, CNT, and the
entire CD, while glomeruli and proximal tubules did not show
any detectable MR expression. GR mRNA was found in all
microdissected sample preparations (Fig. 1).
Speciﬁcity of MR and GR antibodies. To further validate the
mRNA data, we studied MR and GR expression at the protein
level. We took advantage of already available mouse anti-MR
(rMR1–18) (24) and anti-GR antibodies (M-20 and PA1–
511A). The speciﬁcity of the antibodies was conﬁrmed by
using, as a positive control, specimens from a highly differen-
tiated mouse collecting duct cell line (mCCDcl1) with known
functional MR and GR expression (19). Kidneys of transgenic
mice with a conditional deletion of the MR in the collecting
duct (46) and kidneys from mice with a constitutive deletion of
the GR in all cell types (6) served as negative controls (Fig. 2).
Immunoblotting with cell lysates from the mCCD cells showed
that the MR and GR antibodies detect single bands of the
expected sizes of native MR and GR, respectively (Fig. 2A). In
immunoﬂuorescent experiments in mCCD cells, MR and GR
antibodies showed the expected nuclear localization of the
receptors (Fig. 2A). Similarly, MR and GR antibodies showed
a clear nuclear staining pattern in renal tubules of kidneys from
wild-type mice, which was absent in the corresponding cells of
the proper control knockout mouse models (Fig. 2B).
Distribution of MR and GR protein along the rat nephron.
Coimmunostainings with MR or GR antibodies and with
nephron-speciﬁc marker molecules were used to unequivocally
localize the receptors along the rat nephron. Consistent with
the RT-PCR results, the MR was readily detected in cell nuclei
of NKCC2-positive TALs, NCC-positive DCTs, ENaC-posi-
tive CNTs and CCD cells, as well as H-ATPase-positive
intercalated cells (Fig. 3). Among the latter, all subtypes
including type-A and type-B intercalated cells were MR pos-
itive (Fig. 3). The staining pattern and intensities were similar
for CNT and CD. However, the MR-related immunostaining
was usually more pronounced in the segment-speciﬁc cells
than in the intercalated cells. In the latter, staining intensity
varied, but consistent differences between intercalated cell
subtypes were not observed. Proximal tubules were always MR
negative. Occasionally, glomeruli revealed very weak nuclear
staining that we, however, consider as unspeciﬁc as it was
observed rarely and RT-PCR experiments did not show any
detectable MR-related mRNA in glomeruli. In contrast to the
distinct localization of the MR to distal tubules, the GR showed
a ubiquitous expression and was found by immunohistochem-
istry in cell nuclei of cells in glomeruli, proximal tubules, and
distal tubules including TALs, DCTs, CNTs, and CDs. In
DCT, CNT, and CD, both calbindin D28K-positive principal
cells as well as calbindin D28K-negative intercalated cells
showed a nuclear localization of the GR (Fig. 4, A and B).
Interestingly, proximal tubules revealed, in addition to the
nuclear staining, a small rim of immunoﬂuorescence at the
apical cell side. Costainings with phalloidin-FITC, which la-
bels ﬁlamentous actin (F-actin), demonstrated that this GR-
related immunostaining localized to the so-called subapical
compartment, which lies just below the F-actin-rich brush
border (Fig. 4, C–H). Subapical immunostaining was also seen
in perfusion-ﬁxed kidneys of adult mice (not shown), but it was
not visible in the immersion-ﬁxed kidneys of newborn mice
(neither GR/ nor GR/ mice) (Fig. 2). Therefore, we
cannot ﬁnally prove the speciﬁcity of the subapical staining,
but the fact that two different rabbit anti-GR antibodies di-
rected against different epitopes show the same subapical
Fig. 3. Distribution of MR in the renal cortex
of a control rat. Cryostat sections of the kidney
coimmunostained with monoclonal antibodies
against MR (green) and rabbit polyclonal an-
tibodies against the Na-K-2Cl cotransporter
(NKCC2), the NaCl-cotransporter (NCC), the
-subunit of the epithelial sodium channel
(ENaC), and the H-ATPase (all shown in
red) are shown. A: overview. MR is highly
abundant in cell nuclei of NKCC2-positive
TAL (T), NKCC2-negative DCT (D), CN, and
adjacent CD, but is absent from proximal tu-
bule (P). B–D: higher magniﬁcations conﬁrm
that MR is expressed in NCC-positive DCT
(B), -ENaC-positive segment-speciﬁc cells
of the CD (C), and in H-ATPase-positive
intercalated cells of CD (D). Note that MR is
seen in intercalated cells with apical (arrows),
basolateral (arrowhead), and diffuse H-ATPase
immunostaining (asterisk), indicating that all in-
tercalated cell subtypes are MR positive. Scale
bars 	 
20 m.
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staining pattern in rat proximal tubules, which is not seen with
any other of the used rabbit antibodies, gives a high degree of
conﬁdence in the speciﬁcity of the observed staining. Another
indication for the speciﬁcity of the staining is that the subapical
staining is apparently regulated by corticosteroids.
Effect of altered dietary sodium intake. We next tested
whether physiologically relevant variations in plasma aldoste-
rone levels may affect the subcellular localization of MR and
GR. For that purpose, rats were kept for 1 wk on a high-salt
(5% Na) diet, which suppresses aldosterone secretion from
the adrenal glands (25). Surprisingly, a high-salt diet did not
remove the MR from the cell nuclei of either NKCC2-postive
TAL, NCC-positive DCT, ENaC-positive principal, or ENaC-
negative intercalated cells in CNT and CD (Fig. 5). Similarly,
the nuclear localization of GR was not affected in cells of
proximal tubules, TALs, and DCTs (Fig. 6, A–D). Only in
CNTs and CDs, some of the epithelial cells did not show any
nuclear localization of GR any longer. Careful analysis re-
vealed that these cells were the ENaC- and calbindin D28K-
positive segment-speciﬁc cells, while the ENaC- and calbindin
D28K-negative intercalated cells maintained nuclear GR local-
ization (Fig. 6, E–G). Double immunostainings further re-
vealed that the segment-speciﬁc CNT and CD cells lacking
nuclear GR localization are those cells that express high levels
of 11-HSD2 (Fig. 6, H–L). Consistent with this notion, the
nuclear localization of GR varies along the DCT. In the early
DCT (DCT1), where 11-HSD2 expression is low, the nuclear
localization of the GR is strong. However, it vanishes progres-
sively along the late DCT (DCT2) with the increasing 11-
HSD2 levels and becomes ﬁnally almost undetectable in
the end portion of the DCT2, similar to the situation in the
segment-speciﬁc cells of the CNT (Fig. 7, A–D). Thus the
selective lowering of plasma aldosterone concentration by
increased dietary sodium intake has no effect on the subcellular
localization of MR, but removes the GR from the nuclei of
cells expressing high levels of 11-HSD2.
Fig. 4. Distribution of the GR in the renal
cortex of a control rat. Cryostat sections were
costained with rabbit polyclonal antibodies
against GR (red) and mouse monoclonal an-
tibodies against the calcium binding protein
calbindin D28K (CB) or F-actin labeling by
phalloidin-FITC (all in green). A and B: renal
cortex. GR immunostaining is seen in cell
nuclei located in glomeruli (G), proximal tu-
bules (P), in CB-positive DCT (D), and in
CN, in which both CB-positive segment-spe-
ciﬁc CN cells as well as CB-negative interca-
lated cells show nuclear GR labeling. In ad-
dition to this nuclear labeling, proximal tu-
bules (P) reveal a distinct GR immunostaining
at the apical cell side. Higher magniﬁcations
(C–H) resolve that this staining, which is seen
with 2 different anti-GR antibodies (i.e., an-
tibodies M20 and PA1–511), is localized just
below the F-actin-positive brush border in the
so-called subapical compartment. Scale bars 	

20 m.
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Effect of adrenalectomy and aldosterone replacement. We
next tested whether complete deprivation of any endogenous
adrenal aldosterone and corticosterone production might affect
the nuclear localization of MR and GR. For that purpose, rats
were adrenalectomized (ADX). As expected, bilateral ADX
completely removed MR and GR from the cell nuclei of all
renal cell types (Fig. 8, A and C). Interestingly, also the
intensity of the subapical GR immunostaining in proximal
tubules was decreased. Continuous infusion of aldosterone (1
g·kg body wt1·h1) for 4 h rapidly relocated MR and GR to
the cell nuclei, which occurred virtually in all tubular epithelial
cells with known MR and GR expression (Fig. 7, B and D).
Similarly, the aldosterone infusion increased the subapical GR
immunostaining in proximal tubules (Fig. 8D). The aldoste-
rone-induced nuclear translocation was paralleled by a lower
urinary Na/K excretion in aldosterone-treated than in vehi-
cle-treated rats (Fig. 8E), conﬁrming the physiological signif-
icance of the altered subcellular localization of the receptors.
Effect of low- and high-dose corticosterone treatment on
ADX rats. In pilot experiments, we used the same experimental
protocol as above and infused corticosterone at day 2 after
ADX at concentrations ranging from 1 to 100 g·kg body
wt1·h1. To our surprise, even the subphysiological replace-
ment dose of 1 g·kg body wt1·h1 caused a pronounced
nuclear localization of GR and MR in all GR- and MR-
expressing cell types, including the 11-HSD2-positive CNT
and CD cells (data not shown). We speculated that the 2-day
gap between ADX and corticosterone replacement may have
lowered the 11-HSD2 activity due to the absence of its
endogenous substrate. In fact, previous observation in A6 cells
and mCCD cells in vitro supported the idea that maintenance of
high activity of 11-HSD2 depends on the continuous presence
of corticosteroids (19, 20). Accordingly, we changed our ex-
perimental protocol and substituted corticosterone immediately
after ADX. Interestingly, only high-dose corticosterone re-
placement (100 g·kg body wt1·h1) caused nuclear local-
ization of all MR and GR in all epithelial cell types expressing
these receptors. Low-dose corticosterone replacement (1 g·kg
body wt1·h1) induced a nuclear localization of the MR in
ENaC-negative distal tubules as well in the ENaC-positive
ASDN, but located the GR to the nucleus only in proximal
tubules, TALs, DCTs, and intercalated cells, but not in the
classical ASDN cells with strong 11-HSD2 expression (Fig. 9,
A–D). Consistent with the differential regulation of the GR in the
11-HSD2-positive ASDN cells, only high-dose, but not low-
dose corticosterone treatment lowered the urinary Na/K excre-
tion compared with vehicle administration (Fig. 9E).
DISCUSSION
Previous studies localized the MR and GR along the mam-
malian nephron using RNAase protection and ligand-binding
assays on microdissected nephron portions (7, 10–12, 15, 33,
53) and autoradiography, in situ hybridization, and immuno-
histochemistry on kidney sections (4, 13, 32, 37, 55). Together
with data on the localization of the 11-HSD2 (reviewed in
Refs. 4, 14, and 56), the data helped to deﬁne the ASDN.
However, several questions regarding the precise cellular lo-
calization of MR and GR in non-ASDN cells and about the
regulation of the subcellular localization of these receptors by
corticosteroids in the kidney in vivo remained open. In the
present study, we used detailed immunohistochemistry to pro-
vide a comprehensive analysis of the localization and cortico-
steroid-dependent regulation of MR and GR along the rat
nephron. Our study conﬁrms the prominent expression of MR,
GR, and 11-HSD2 in the ASDN. Moreover, we show for the
ﬁrst time convincingly the localization of MR and GR in all
types of intercalated cells and establish the subcellular distri-
bution pattern of MR and GR in ASDN and several non-ASDN
cell types. Moreover, the present data reveal a distinct pattern
of differential regulation of the subcellular localization of MR
and GR in the various renal epithelial cell types, which allows
inferring on sites and mechanisms of the complex activity of
these receptors along the renal tubule.
Cellular localization of MR. The prominent localization of
the MR in ENaC-positive ASDN cells is not surprising. It
agrees with previous data and supports the present concept of
aldosterone action (56). However, our study reveals MR ex-
pression also in the TALs and in intercalated cells, which
express no or very little 11-HSD2 and which are considered
Fig. 5. Detection of the MR in the renal
cortex of a rat kept for 5 days on a high-NaCl
(5% Na) diet. Cryostat sections costained
with mouse monoclonal antibodies against
MR (green) and rabbit polyclonal antibodies
against either NKCC2 (A), NCC (B), or
-ENaC (C; all in red). MR is present in the
cell nuclei of NKCC2-positive TAL (T) cells,
NCC-positive DCT (D) cells, and ENaC-
positive segment-speciﬁc cells and ENaC-
negative intercalated cells in CN. Scale bar	
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not to belong to the classic aldosterone target cells. Strong MR
mRNA and protein expression in the TAL has been previously
reported (10, 11, 13, 32, 37, 55), but other RT-PCR (53),
immunohistochemical (4), and hormone binding data (39)
suggested a rather low abundance of MR protein at this site
compared with the classic ASDN. Now, we found a surpris-
ingly strong immunostaining for the MR in the TAL, which
was only slightly lower than that seen in the classic ASDN
cells. The strong MR expression in the TAL is consistent with
previous reports describing a profound stimulatory action of
aldosterone on TAL sodium transport (51, 61) but contrasts
with other studies that did not reveal any effect of aldosterone
on the expression and activity of the Na-K-ATPase and the
potassium transport in the TAL of ADX rabbits and rats,
respectively (9, 21, 54). Thus the physiological role of aldo-
sterone in the TAL remains obscure. Our observation that the
subcellular localization of MR is only regulated by aldosterone
when glucocorticoids are absent (i.e., in ADX animals), indi-
cates that physiological variations of aldosterone in intact
animals are not sufﬁcient to elicit aldosterone-speciﬁc MR-
mediated transcriptional effects in the TAL.
Another surprising observation in our study is the prominent
localization of the MR in all types of intercalated cells. Al-
though ex vivo studies on immunoisolated type-B intercalated
cells suggested the expression of MR in at least this subtype of
intercalated cells (41), previous immunohistochemical studies
consistently failed to detect any MR localization within inter-
calated cells in the kidney (4, 13, 37). Aldosterone is known to
stimulate renal proton excretion (52), but this effect is thought
to be indirect and related to activation of ENaC-dependent
sodium transport in principal cells, which increases the elec-
trochemical driving force for proton secretion by intercalated
cells. Given the low expression level of 11-HSD2 and the
pattern of MR and GR regulation within intercalated cells, it is
unlikely that aldosterone has signiﬁcant direct genomic effects on
intercalated cells, at least in the physiological context of several-
fold higher plasma levels of corticosterone than aldosterone.
However, MR expression in intercalated cells may become rele-
vant in patients with pharmacological (e.g., by spironolactone) or
genetic (i.e., pseudohypoaldosteronism type 1) MR inactivation.
Under these conditions, the loss of MR function in intercalated
cells may contribute to the development of metabolic acidosis that
Fig. 6. Detection of the GR in the renal cortex
of rats kept for 5 days on a high-NaCl (5%
Na) diet. Immunostainings for GR (green)
and segment- and cell-speciﬁc marker mole-
cules (red or blue) on pairs of consecutive
cryosections are shown. A–D: 2 pairs of con-
secutive cryosections show that GR is present
in cell nuclei of NKCC2-positive-positive TAL
(T) cells (A and B) and NCC-positive DCT
cells (C and D). E and F: 1 pair of consecutive
cryosections stained with either a rabbit-poly-
clonal antibody against -ENaC (E) or costained
with mouse monoclonal antibodies against CB
(F) and rabbit polyclonal antibodies against GR
(G). GR is seen in the cell nuclei of proximal
tubules (P) and in -ENaC- and CB-negative
intercalated cells (arrows) of CN. -ENaC- and
CB-positive CN cells (arrowheads) do not
show any nuclear GR labeling. H–L: cryostat
section costained with sheep polyclonal anti-
bodies against 11-hydroxysteroid dehydroge-
nase type 2 (11-HSD2; H), rabbit polyclonal
antibodies against GR (M-20; I), and the DNA
dye DAPI (K) shown in separate red, green and
blue colors (H–K) or in a merged image (L).
The GR is seen in the cell nuclei of only those
cells that do not express 11-HSD2. Scale bar	
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is frequently seen in these patients (23, 44). Whether the MR may
also contribute to the rapid nongenomic effects of aldosterone in
intercalated cells remains elusive (60). Thus additional stud-
ies are warranted to address the yet unclear physiological
relevance of the MR in the TAL and in intercalated cells.
The recent generation of a transgenic mouse model with
ﬂoxed alleles for the MR may allow further addressing the
cell type-speciﬁc roles of the MR (46).
Cellular localization of GR. The GR is thought to be ex-
pressed in virtually all cell types of the mammalian organism.
Hence, it was surprising that immunohistochemical studies failed
to detect the GR in proximal tubules (13), although mRNA
analysis (10, 53) and autoradiographic binding studies (15, 33)
clearly indicated that the GR is present in proximal tubules like in
all other renal epithelial cells. To explain these ﬁndings, Farman
and coworkers (13) speculated that the proximal tubule may
express a GR isoform that their monoclonal mouse antibody may
not bind to because the recognized epitope is either lacking or
masked by interacting proteins, for example. In the present study,
we used two rabbit polyclonal antibodies directed against different
epitopes and could now unequivocally demonstrate that the GR is
abundant at the protein level in all renal cells types, including
proximal tubular cells. Interestingly, in proximal tubules the GR
accumulated not only in cell nuclei, but also in the region of the
subapical compartment (SAC). The SAC is formed by a network
of tubulovesicular structures involved in endocytotic and exocy-
totic trafﬁcking of membrane vesicles and membrane proteins
(28, 29). Moreover, the SAC participates to receptor-mediated
endocytosis of plasma proteins, which have been ﬁltered in renal
glomeruli (5). It is unlikely that the GR is an endo- or exocytosed
protein, but the accumulation of the GR within the SAC may
position the receptor perfectly well to rapidly bind ligands that
enter the cells from the tubular lumen. This luminal ligand uptake
may not only concern corticosteroids that were freely ﬁltered at
the glomeruli but also those that were ﬁltered bound to plasma
proteins. In fact, there is increasing evidence that steroid
hormones may enter certain cell types not only by free
diffusion but also by receptor-mediated endocytosis of their
carrier proteins (59). Notably, circulating corticosteroids are
bound 90% to corticosteroid-binding globulin (CBG),
which has a molecular mass of 55 kDa (27), which is just
below the 60 kDa cut-off of the glomerular ﬁlter. There is
experimental evidence for glomerular ﬁltration of plasma
protein-bound corticosteroids (17), and binding of CBG to
renal cell membranes (50) and localization of CBG in the
subapical region of proximal tubule cells have been dem-
onstrated (49). Independent of the underlying uptake mech-
anism and the subsequent fate of the corticosteroid hor-
mones, the strong dependence of the subapical localization
of the GR on the presence of circulating corticosteroids (ﬁg.
7) suggests that the GR is involved in the reuptake of
corticosteroids ﬁltered at the glomeruli, which may impact
on the bioavailablity of the hormones locally at the level of
the proximal tubule, but also along the downstream nephron
portions.
Corticosteroid-dependent regulation of MR and GR nuclear
localization. Our data show that corticosteroids control the
nuclear localization of MR and GR not only in cell systems in
vitro, as previously reported (16, 43), but also in the kidney in
vivo. By and large, the present ﬁndings support the classic
concepts of MR and GR regulation by corticosteroid hor-
mones. However, with respect to the ASDN, our data indicate
that the current textbook dogma that mineralocorticoids act
mainly via the MR, which is protected from activation by
glucocorticoids due to the action of 11-HSD2, may need
additional reﬁnement. Using a set of experiments in intact rats
on different sodium intakes and in ADX rats treated with
different corticosterone replacement doses, we provide evi-
Fig. 7. Detection of the GR along the DCT of
a rat kept for 5 days on a high-NaCl (5% Na)
diet. Immunostainings with rabbit polyclonal
antibodies against NCC (A), sheep polyclonal
antibodies against 11-HSD2 (B), mouse
monoclonal antibodies against CB (C), and
rabbit polyconal antibodies against GR (M-
20; D) on either consecutive (A, B, C/D) or
the same (C and D) cryosections are shown.
The DCT begins at the end of the TAL (T)
and is characterized along its entire length by
the expression of the NCC. The early DCT (1)
and the late DCT (2) can be distinguished
based on the different expression levels of
11-HSD2 and CB, which are low in early
DCT (1) and are high in late DCT (2). The
GR is highly abundant in the cell nuclei of
proximal tubules (P), TAL (T), and early
DCT (1), but vanishes along the late DCT (2)
in parallel with the increasing 11-HSD2 lev-
els. In the end portion of the late DCT (2*),
nuclear GR localization is barely visible,
which is similar to the CN. In the latter, only
the CB-negative intercalated cells (arrows)
show bright nuclear immunostaining for the
GR. Scale bar 	 
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dence that in the kidney in vivo it is not the MR, but mainly the
GR, the subcellular localization of which is controlled by
physiological variations in plasma aldosterone levels and that it
is mainly the GR which is protected by the 11-HSD2 from
circulating corticosteroids. This conclusion may surprise at
ﬁrst glance, but it is fully compatible with the current knowl-
edge about the physiological plasma concentrations of aldoste-
rone and corticosterone, the Kd values of MR and GR, and the
presumed activity of 11-HSD2. Under standard conditions,
rats have plasma concentrations of aldosterone and corticoste-
rone in the range of 
1 and 1,000 nM, respectively (25),
whereby only part of the corticosterone is thought to be active
since most is bound to CBG. The MR and GR bind both
hormones with more or less similar afﬁnities, but with clearly
different Kd values [i.e., MR (Kd 0.5–3 nM) and GR (Kd 20–65
nM)] (1). As pointed out by Funder (18), it is well possible that
11-HSD2 does not achieve a 100% inactivation of cortico-
sterone before it can bind to the MR and GR. Even if 99%
Fig. 8. Effect of aldosterone infusion on subcellular
localization of MR and GR (A–D) and urinary Na and
K excretion (E) in adrenalectomized (ADX) rats.
Immmunostainings with mouse monoclonal antibodies
against MR (A and B) and rabbit polyclonal antibodies
(M-20) against GR (C and D) in the renal cortex of ADX
rats that received either vehicle only (left) or an infusion
of aldosterone (1 g·kg body wt1·h1; right) 3 h before
ﬁxation of the kidneys as described in MATERIALS AND
METHODS are shown. In vehicle-treated ADX rats, MR
and GR are absent from the cell nuclei of all renal
epithelial cells including those of proximal tubules (P)
and CN. Three hours after aldosterone infusion, MR and
GR are located in the cell nuclei. Three hours after
aldosterone infusion was started, the ratio of urinary Na
to urinary K is signiﬁcantly lower in aldosterone- than
in vehicle-treated rats (mean  SE, n 	 3/group, *P 
0.05 vs. vehicle). Scale bar 	 
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efﬁciency is achieved, the remaining intracellular corticoste-
rone concentrations in ASDN cells are likely still high enough
to bind to and activate most of the MR, but only a small portion
of the GR and hence leave it available for activation by
aldosterone. Of course, immunoﬂuorescence is not sensitive
enough to exclude a further increase in the nuclear localization
of MR with increasing plasma aldosterone levels. Moreover, it
remains possible that changed aldosterone levels control the
Fig. 9. Effect of low-dose (1 g·kg body wt1·h1) and
high-dose (100 g·kg body wt1·h1) corticosterone
replacement on subcellular localization of MR and GR
(A–D) and urinary Na and K excretion (E) in ADX
rats. Coimmunostainings with mouse monoclonal anti-
bodies against MR are shown in green, rabbit poly-
clonal antibodies against -ENaC in red (A and B), and
coimmunostainings with rabbit polyclonal antibodies
(M-20) against GR are shown in green and sheep
polyclonal antibodies against 11-HSD2 in red (C and
D). In ADX rats with low and high corticosterone
replacement, MR is located in the cell nuclei of both
ENaC-positive CN and ENaC-negative intercalated
cells (A and B). Low-dose corticosterone replacement
results in nuclear localization of the GR in proximal
tubule (P), DCT (D), and intercalated cells (arrows),
which express no or only weak 11-HSD2, but not in
CN cells with strong 11-HSD2 immunostaining (as-
terisk in C). Only when corticosterone is replaced at
high doses, segment-speciﬁc CN cells with high 11-
HSD2 expression also show nuclear localization of the
GR (asterisk in D). E: urinary Na/urinary K excre-
tion in ADX rats that received by osmotic minipumps
either vehicle, low-dose corticosterone (1 g·kg body
wt1·h1), or high-dose corticosterone (100 g·kg
body wt1·h1) replacement for 48 h post-ADX. Urine
samples were collected in metabolic cages during the
last 24 h of the experiment as described in MATERIALS
AND METHODS (means  SE, n 	 3/group, *P  0.05
vs. vehicle). Scale bar 	 
20 m.
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binding of MR to hormone-responsive elements of target genes
independently of effects on subcellular localization. In this
context, the differential subcellular localization of MR and GR
in ASDN cells may even provide an important means by which
mineralocorticoid speciﬁcity is conferred to the MR. The
preferential nuclear localization of the MR under physiological
conditions (i.e., with intact adrenal glands) would require that
corticosterone diffuses through the cell before it can bind to the
MR. This may increase the chance that the 11-HSD2 can
fully inactivate corticosterone before it reaches the nucleus.
Thus nuclear MR may respond nicely to physiological varia-
tions in aldosterone while the GR is shufﬂing back and forth,
linked to altered hormone levels. Mineralocorticoid selectivity
might be conferred to the MR also independently of 11
-HSD2 by a functional preference of the receptor for aldo-
sterone, as indicated by ﬁndings in cell culture assays (38) and
in vivo experiments (26).
Role of MR and GR in aldosterone action. The coexpression
and differential regulation of MR and GR in ASDN cells raise
the apparent question of the role of both receptors and whether
both receptors are required for the physiological response
to aldosterone. Geering and coworkers (22) were the ﬁrst to
suggest that the occupancy of both receptors is necessary to
achieve a full biological response. Although there is evidence
for some functional compensation of the GR in MR/ mice
(48), both receptors appear to be important for the control of
sodium transport in the ASDN, as indicated by recent ﬁndings
in mouse models with targeted inactivation of the MR in the
renal collecting system (46), overexpression of the GR in the
collecting duct (42), or with pharmacological inhibition of
either the MR or the GR in ACTH-induced Cushing’s syn-
drome (2). Based on recent experiments in a mouse collecting
duct cell line, Gaeggeler and coworkers (19) came up with the
idea that the exclusive occupancy of MR provides a limited
increase in sodium transport which is adequate for (circadian)
maintenance requirements under low plasma aldosterone lev-
els, while occupancy of both receptors would lead to the
maximal response needed for maximum sodium retention un-
der severe salt restriction and/or stress. This model, derived
from in vitro studies, would be fully compatible with our in
vivo ﬁndings on the regulation of the subcellular localization of
MR and GR along the nephron. Differential dimerization of
MR and GR may contribute to a graded response of the ASDN
to altered plasma aldosterone levels (47). In fact, dimerization
of steroid receptors is required for binding of the ligand-bound
receptor complexes to hormone-response elements and activa-
tion of gene transcription. The MR and GR can either ho-
modimerize (MR-MR) or heterodimerize (MR-GR). Experi-
ments in which variable proportions of each receptor cDNA
were transfected to test their efﬁciency on a reporter gene
revealed that transactivation activity was dependent on the
nature of the dimer likely formed (14). In some cases, tran-
scription synergy was evidenced on MR and GR cotransfec-
tion, whereas, in other cases, it was shown that MR inhibits GR
transcriptional activity. In addition, heterodimers might be
formed with only one receptor entity in a liganded state,
increasing the diversity of steroid hormone effects (14). Thus a
differential regulation of receptor translocation to the cell
nucleus would allow for a differential regulation of receptor
homo- and/or heterodimerization, which could contribute to
the complexity of corticosteroid hormone action in the kidney.
In conclusion, our study provides a detailed analysis of the
cellular and subcellular localization of the MR and GR along
the nephron and supports the concept that ligand-induced
nuclear translocation of MR and GR are important components
of MR and GR regulation in the kidney. In the ASDN,
11-HSD2 protects mainly the GR from binding of corticoste-
rone and leaves it available for activation and nuclear redistri-
bution in response to increased plasma aldosterone levels.
Differential regulation of MR and GR may alter the level of
heterodimerization of the receptors and hence may contribute
to the complexity of the corticosteroid effects on ASDN
function.
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